IMV News and Press, IMV Inc. From 03/09/22

IMV’s DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies Clinical data from the Company’s basket study in advanced, metastatic bladder cancer will be presented at the ...

Event will feature Michael Kalos, Ph.D., member of IMV’s Board of Directors and internationally recognized expert in T cell therapy and immunotherapy Live webinar on Thursday, February 24th @ 8amET, registration details below IMV Inc. (Nasdaq: IMV; TS...

First patient with relapsed/refractory DLBCL received treatment with maveropepimut-S (MVP-S) in combination with KEYTRUDA, advancing IMV’s lead compound on the path to a registration trial IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfol...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers today announced that members of IMV’s executive management team will be presenting virtually at...

IMV (NASDAQ:IMV) has appointed Andrew Hall as Chief Executive Office and Director of the Board, effective January 1, 2022. Chief Executive Officer of IMV, “There is significant potential for IMV and the DPX platform to deliver differentiated therapies to treat a broad range of cancers....

IMV Inc. (NASDAQ: IMV; TSX: IMV), (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and blood cancers, announced today that its Board of Directors has ...

Reliance Global (NASDAQ:RELI) +85%. Aridis Pharmaceuticals (NASDAQ:ARDS) +72% after its antibody cocktail retains effectiveness against Omicron variant. Quoin Pharmaceuticals (NASDAQ:QNRX) +44%. Cassava Sciences (NASDAQ:SAVA) +40% Cassava Sciences, Biofrontera rise amid so...

IMV (NASDAQ:IMV) announces the finalization of the basket clinical study evaluating maveropepimut-S (MVP-S) in combination with Merck’s Keytruda in patients with metastatic bladder and Micro-Satellite Instability High (MSI-H) solid tumors. Shares up 6.3% premarket at $1....

Clinical benefit (complete responses, partial responses, and stable disease) observed in metastatic bladder cancer patients, including those who had received prior immune checkpoint inhibitor therapy IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a por...

This facility supports the advancement of IMV’s lead candidate, maveropepimut-S (MVP-S) across a range of cancer indications, and the development of new DPX-based immunotherapies against cancer IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a po...